

Ilies Benotmane

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1970701/publications.pdf>

Version: 2024-02-01

32
papers

1,741
citations

361413

20
h-index

434195

31
g-index

39
all docs

39
docs citations

39
times ranked

2711
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series. <i>Annals of Internal Medicine</i> , 2022, 175, 455-456.	3.9	98
2	Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients. <i>Science Translational Medicine</i> , 2022, 14, eabl6141.	12.4	52
3	Occurrence of De novo Donor-Specific Antibodies After COVID-19 in Kidney Transplant Recipients Is Low Despite Immunosuppression Modulation. <i>Kidney International Reports</i> , 2022, 7, 983-992.	0.8	12
4	A fourth SARS-CoV-2 mRNA vaccine in strictly seronegative kidney transplant recipients. <i>Kidney International</i> , 2022, 101, 825-826.	5.2	25
5	A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients. <i>Kidney International</i> , 2022, 101, 1073-1076.	5.2	44
6	Combining predictive markers for severe COVID-19: Torquetenovirus DNA load and SARS-CoV-2 RNAemia. <i>Journal of Clinical Virology</i> , 2022, 148, 105120.	3.1	7
7	Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant. <i>Kidney International</i> , 2022, 102, 442-444.	5.2	34
8	Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 2675-2681.	4.7	48
9	Prediction of Vaccine Response and Development of a Personalized Anti-SARS-CoV-2 Vaccination Strategy in Kidney Transplant Recipients: Results from a Large Single-Center Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 1107.	2.5	5
10	Intravenous immunoglobulin as a preventive strategy against BK virus viremia and BKV-associated nephropathy in kidney transplant recipients—Results from a proof-of-concept study. <i>American Journal of Transplantation</i> , 2021, 21, 329-337.	4.7	24
11	SARS-CoV-2 viral dynamics in immunocompromised patients. <i>American Journal of Transplantation</i> , 2021, 21, 1667-1669.	4.7	23
12	Cerebrospinal Fluid Features in Patients With Coronavirus Disease 2019 and Neurological Manifestations: Correlation with Brain Magnetic Resonance Imaging Findings in 58 Patients. <i>Journal of Infectious Diseases</i> , 2021, 223, 600-609.	4.0	47
13	Is COVID-19 infection more severe in kidney transplant recipients?. <i>American Journal of Transplantation</i> , 2021, 21, 1295-1303.	4.7	190
14	Cytokine release syndrome—associated encephalopathy in patients with COVID-19. <i>European Journal of Neurology</i> , 2021, 28, 248-258.	3.3	114
15	SARS-Cov-2 Seroprevalence in a French Kidney Transplant Center Located Within a “High Risk” Zone. <i>Transplantation</i> , 2021, Publish Ahead of Print, 2165-2169.	1.0	0
16	COVID-19 in a kidney transplant recipient treated with eculizumab for atypical hemolytic uremic syndrome: a case report. <i>Journal of Nephrology</i> , 2021, 34, 1045-1048.	2.0	4
17	Long-term shedding of viable SARS-CoV-2 in kidney transplant recipients with COVID-19. <i>American Journal of Transplantation</i> , 2021, 21, 2871-2875.	4.7	33
18	Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. <i>Kidney International</i> , 2021, 99, 1498-1500.	5.2	163

#	ARTICLE	IF	CITATIONS
19	Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. <i>Kidney International</i> , 2021, 99, 1487-1489.	5.2	126
20	Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19. <i>American Journal of Transplantation</i> , 2021, 21, 3808-3810.	4.7	20
21	Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy. <i>Kidney International</i> , 2021, 100, 466-468.	5.2	60
22	Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1063.	7.4	300
23	Persistence of SARS-CoV-2 antibodies in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 2307-2310.	4.7	20
24	Biomarkers of Cytokine Release Syndrome Predict Disease Severity and Mortality From COVID-19 in Kidney Transplant Recipients. <i>Transplantation</i> , 2021, 105, 158-169.	1.0	34
25	Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 98, 115181.	1.8	29
26	In-depth virological assessment of kidney transplant recipients with COVID-19. <i>American Journal of Transplantation</i> , 2020, 20, 3162-3172.	4.7	68
27	Is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present intraperitoneally in patients with coronavirus disease 2019 (COVID-19) infection undergoing emergency operations?. <i>Surgery</i> , 2020, 168, 220-221.	1.9	25
28	Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab. <i>Kidney International</i> , 2020, 98, 508-509.	5.2	17
29	First case of COVID-19 in a kidney transplant recipient treated with belatacept. <i>American Journal of Transplantation</i> , 2020, 20, 1944-1946.	4.7	55
30	Le BK virus en greffe nationale. <i>Revue Francophone Des Laboratoires</i> , 2019, 2019, 44-52.	0.0	0
31	Letter to the Editor concerning Cytomegalovirus prevention strategies and the risk of BK polyomavirus viremia and nephropathy. <i>American Journal of Transplantation</i> , 2019, 19, 3438-3439.	4.7	1
32	Intravenous Immunoglobulin Administration Significantly Increases BKPyV Genotype-Specific Neutralizing Antibody Titers in Kidney Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	20